

Erratum

In the article by Igawa et al., entitled 'Comparison of the efficacy of gefitinib in patients with non-small cell lung cancer according to the type of epidermal growth factor receptor mutation' [Oncology 2014;87:215–223, DOI: 10.1159/000362603], the overall survival of patients with the L858R point mutation was 22.7 months as shown in figure 4 and not 27.7 months as stated in the abstract.

The authors apologize for this inconsistency.